Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 2,500 Shares of Stock

April 8, 2026 by InsiderTrades.com

Key Points

CEO insider sale: iRadimed CEO Roger Susi sold 5,000 shares on April 6 at an average price of $96.02 for $480,100, reducing his stake by 0.22% to 2,220,000 shares; the transaction was executed under a pre-arranged Rule 10b5-1 plan.
Operational results and payout: The company beat Q4 estimates with $0.54 EPS on $22.69M revenue, set Q1 2026 guidance of $0.440–0.480 and FY 2026 guidance of $2.060–2.210 EPS, and raised its quarterly dividend to $0.20 (annualized $0.80, ~0.9% yield).
Market view: Shares opened at $93.49 (down ~2.3%), iRadimed has a $1.20B market cap and a P/E of 53.42, analysts have a consensus "Buy" with a $120 target, and institutional investors own about 92.34% of the stock.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $94.84, for a total value of $237,100.00. Following the transaction, the chief executive officer directly owned 2,217,500 shares in the company, valued at approximately $210,307,700. This trade represents a 0.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Down 2.3%

Shares of NASDAQ IRMD opened at $93.49 on Wednesday. The business's 50 day moving average price is $99.50 and its two-hundred day moving average price is $91.90. The company has a market cap of $1.20 billion, a PE ratio of 53.42 and a beta of 1.11. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, research analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were given a $0.20 dividend. The ex-dividend date of this dividend was Monday, February 23rd. This is a positive change from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed's dividend payout ratio (DPR) is currently 45.71%.

Analysts Set New Price Targets

Several research firms have recently commented on IRMD. Lake Street Capital reaffirmed a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of iRadimed in a research report on Monday, December 29th. Roth Mkm reaffirmed a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Freedom Capital raised iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $120.00.

View Our Latest Stock Report on IRMD

Institutional Investors Weigh In On iRadimed

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of iRadimed by 1.0% in the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider's stock valued at $40,313,000 after buying an additional 5,475 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider's stock valued at $24,893,000 after buying an additional 205,783 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of iRadimed by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider's stock valued at $21,123,000 after buying an additional 2,578 shares during the period. Ranger Investment Management L.P. boosted its stake in shares of iRadimed by 7.4% in the second quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider's stock valued at $12,845,000 after buying an additional 14,730 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of iRadimed by 37.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider's stock valued at $19,964,000 after buying an additional 55,426 shares during the period. 92.34% of the stock is currently owned by institutional investors.

About iRadimed

(Get Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.